Wedbush Analysts Raise Earnings Estimates for argenex

argenex SE (NASDAQ:ARGX) – Wedbush lifted their Q4 2025 earnings per share (EPS) estimates for shares of argenex in a report issued on Friday, November 14th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of $6.48 for the quarter, up from their previous estimate of $6.15. Wedbush has a “Outperform” rating and a $1,000.00 price objective on the stock. The consensus estimate for argenex’s current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex’s Q1 2026 earnings at $7.36 EPS, Q2 2026 earnings at $8.16 EPS, Q3 2026 earnings at $8.95 EPS, Q4 2026 earnings at $9.60 EPS, FY2026 earnings at $34.10 EPS, FY2027 earnings at $46.09 EPS and FY2028 earnings at $61.81 EPS.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The company had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.07 billion.

Several other research firms have also recently weighed in on ARGX. Morgan Stanley boosted their price objective on shares of argenex from $766.00 to $1,040.00 and gave the company an “overweight” rating in a report on Wednesday, October 1st. Royal Bank Of Canada boosted their target price on shares of argenex from $850.00 to $860.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Stifel Nicolaus set a $882.00 price target on argenex in a research note on Thursday, September 18th. Evercore ISI upped their price objective on argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Finally, Deutsche Bank Aktiengesellschaft downgraded argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $903.78.

argenex Stock Performance

ARGX opened at $929.61 on Monday. The company’s 50-day simple moving average is $802.57 and its two-hundred day simple moving average is $674.85. The stock has a market capitalization of $57.24 billion, a P/E ratio of 39.91, a P/E/G ratio of 0.93 and a beta of 0.45. argenex has a 52-week low of $510.05 and a 52-week high of $934.13.

Institutional Trading of argenex

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Capital World Investors lifted its position in shares of argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock valued at $1,445,113,000 after buying an additional 8,422 shares in the last quarter. Wellington Management Group LLP raised its stake in argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after acquiring an additional 324,653 shares during the period. Bank of America Corp DE raised its stake in argenex by 1.9% during the 3rd quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock worth $252,525,000 after acquiring an additional 6,259 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in argenex by 114.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after purchasing an additional 158,476 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.